Gt Biopharma Stock Performance
| GTBP Stock | USD 2.06 0.05 2.37% |
The company owns a Beta (Systematic Risk) of 0.35, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, GT Biopharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding GT Biopharma is expected to be smaller as well. At this point, GT Biopharma has a negative expected return of -0.25%. Please make sure to check out GT Biopharma's information ratio, as well as the relationship between the potential upside and rate of daily change , to decide if GT Biopharma performance from the past will be repeated sooner or later.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days GT Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's fundamental drivers remain relatively invariable which may send shares a bit higher in March 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
Actual Historical Performance (%)
One Day Return (2.37) | Five Day Return (9.65) | Year To Date Return (29.93) | Ten Year Return (100.00) | All Time Return (100.00) |
Last Split Factor 1:30 | Dividend Date 2017-08-21 | Last Split Date 2024-02-05 |
1 | Acquisition by Berk Gregory of 50000 shares of GT Biopharma at 6.33 subject to Rule 16b-3 | 10/31/2024 |
2 | Acquisition by Berk Gregory of 278058 shares of GT Biopharma subject to Rule 16b-3 | 11/13/2024 |
3 | GT Biopharma inks clinical trial agreement for cancer treatment - Investing.com | 11/21/2024 |
4 | Insider Trading | 11/27/2024 |
5 | Disposition of 50000 shares by Weldon Steven W of GT Biopharma at 0.28 subject to Rule 16b-3 | 12/17/2024 |
6 | Biotech Stocks Surging in September - AccessWire | 12/31/2024 |
7 | GT Biopharma, Inc. Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies - Marketscr... | 01/27/2025 |
| Begin Period Cash Flow | 5.7 M |
GTBP |
GT Biopharma Relative Risk vs. Return Landscape
If you would invest 305.00 in GT Biopharma on November 2, 2024 and sell it today you would lose (99.00) from holding GT Biopharma or give up 32.46% of portfolio value over 90 days. GT Biopharma is currently does not generate positive expected returns and assumes 10.0083% risk (volatility on return distribution) over the 90 days horizon. In different words, 89% of stocks are less volatile than GTBP, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
GT Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for GT Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as GT Biopharma, and traders can use it to determine the average amount a GT Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0252
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | GTBP |
Estimated Market Risk
| 10.01 actual daily | 89 89% of assets are less volatile |
Expected Return
| -0.25 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average GT Biopharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of GT Biopharma by adding GT Biopharma to a well-diversified portfolio.
GT Biopharma Fundamentals Growth
GTBP Stock prices reflect investors' perceptions of the future prospects and financial health of GT Biopharma, and GT Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on GTBP Stock performance.
| Return On Equity | -1.31 | ||||
| Return On Asset | -0.61 | ||||
| Current Valuation | (5.17 M) | ||||
| Shares Outstanding | 2.23 M | ||||
| Price To Book | 2.20 X | ||||
| EBITDA | 5.98 M | ||||
| Net Income | (7.6 M) | ||||
| Cash And Equivalents | 23.73 M | ||||
| Cash Per Share | 0.76 X | ||||
| Total Debt | 58 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 2.78 X | ||||
| Book Value Per Share | 5.41 X | ||||
| Cash Flow From Operations | (8.85 M) | ||||
| Earnings Per Share | (7.39) X | ||||
| Market Capitalization | 6.23 M | ||||
| Total Asset | 14.11 M | ||||
| Retained Earnings | (682.07 M) | ||||
| Working Capital | 7.42 M | ||||
About GT Biopharma Performance
Assessing GT Biopharma's fundamental ratios provides investors with valuable insights into GT Biopharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the GT Biopharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 61.05 | 86.22 | |
| Return On Tangible Assets | (0.62) | (0.65) | |
| Return On Capital Employed | (2.09) | (2.19) | |
| Return On Assets | (0.48) | (0.46) | |
| Return On Equity | (1.17) | (1.23) |
Things to note about GT Biopharma performance evaluation
Checking the ongoing alerts about GT Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for GT Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| GT Biopharma generated a negative expected return over the last 90 days | |
| GT Biopharma has high historical volatility and very poor performance | |
| GT Biopharma has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (7.6 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| GT Biopharma currently holds about 23.73 M in cash with (8.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76. | |
| Roughly 68.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: GT Biopharma, Inc. Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies - Marketscreener.com |
- Analyzing GT Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether GT Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining GT Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating GT Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of GT Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of GT Biopharma's stock. These opinions can provide insight into GT Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for GTBP Stock Analysis
When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.